scispace - formally typeset
Search or ask a question
Author

Amene Majidipur

Bio: Amene Majidipur is an academic researcher from Paris 12 Val de Marne University. The author has contributed to research in topics: Cancer & Taxane. The author has an hindex of 1, co-authored 1 publications receiving 1 citations.

Papers
More filters
Journal ArticleDOI
28 Jul 2021-Cancers
TL;DR: In this paper, the role of extracellular vesicles (EVs) in therapeutic resistance of advanced prostate cancer and their use to find biomarkers able to predict these resistances was discussed.
Abstract: Prostate cancer (PCa) is the second most frequent cancer and the fifth leading cause of cancer death among men worldwide. At first, advanced PCa is treated by androgen deprivation therapy with a good initial response. Nevertheless, recurrences occur, leading to Castrate-Resistance Prostate Cancer (CRPC). During the last decade, new therapies based on inhibition of the androgen receptor pathway or taxane chemotherapies have been used to treat CRPC patients leading to an increase in overall survival, but the occurrence of resistances limits their benefits. Numerous studies have demonstrated the implication of extracellular vesicles (EVs) in different cancer cellular mechanisms. Thus, the possibility to isolate and explore EVs produced by tumor cells in plasma/sera represents an important opportunity for the deciphering of those mechanisms and the discovery of biomarkers. Herein, we summarized the role of EVs in therapeutic resistance of advanced prostate cancer and their use to find biomarkers able to predict these resistances.

4 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: In this paper, the mechanism of AK-I-190 was clarified using various types of spectroscopic and biological evaluations, which indicated the clinical relevance of topoisomerase II catalytic inhibitors in androgen receptor-negative prostate cancer.
Abstract: Castration-resistant prostate cancer (CRPC) is a clinical challenge in treatment because of its aggressive nature and resistance to androgen deprivation therapy. Topoisomerase II catalytic inhibitors have been suggested as a strategy to overcome these issues. We previously reported AK-I-190 as a novel topoisomerase II inhibitor. In this study, the mechanism of AK-I-190 was clarified using various types of spectroscopic and biological evaluations. AK-I-190 showed potent topoisomerase II inhibitory activity through intercalating into DNA without stabilizing the DNA-enzyme cleavage complex, resulting in significantly less DNA toxicity than etoposide, a clinically used topoisomerase II poison. AK-I-190 induced G1 arrest and effectively inhibited cell proliferation and colony formation in combination with paclitaxel in an androgen receptor-negative CRPC cell line. Our results confirmed that topoisomerase II catalytic inhibition inhibited proliferation and induced apoptosis of AR-independently growing prostate cancer cells. These findings indicate the clinical relevance of topoisomerase II catalytic inhibitors in androgen receptor-negative prostate cancer.

6 citations

Journal ArticleDOI
Liuxi Chu, Xin Shu, Yao Huang, Tong Chu, Meina Ge, Qin Lu 
TL;DR: In this article , the potential use of exosomal sex steroids in urinary exosomes as biomarkers was investigated for the prediction of early-stage PCa to assist in clinical diagnosis.

4 citations

Journal ArticleDOI
TL;DR: NCL was overexpressed in PCa tissues compared to the normal tissues, but no prognostic values were demonstrated, and nine genes were highly co-expressed with NCL in patient tissues and tumor prostate cell lines.
Abstract: Prostate cancer (PCa) is the second most frequent cancer and the fifth leading cause of cancer death in men worldwide. If local PCa presents a favorable prognosis, available treatments for advanced PCa display limiting benefits due to therapeutic resistances. Nucleolin (NCL) is a ubiquitous protein involved in numerous cell processes, such as ribosome biogenesis, cell cycles, or angiogenesis. NCL is overexpressed in several tumor types in which it has been proposed as a diagnostic and prognostic biomarker. In PCa, NCL has mainly been studied as a target for new therapeutic agents. Nevertheless, little data are available concerning its expression in patient tissues. Here, we investigated the expression of NCL using a new cohort from Mondor Hospital and data from published cohorts. Results were then compared with NCL expression using in vitro models. NCL was overexpressed in PCa tissues compared to the normal tissues, but no prognostic values were demonstrated. Nine genes were highly co-expressed with NCL in patient tissues and tumor prostate cell lines. Our data demonstrate that NCL is an interesting diagnostic biomarker and propose a signature of genes co-expressed with NCL.

3 citations

Journal ArticleDOI
TL;DR: Extracellular vesicles (EV) are established as intercellular messengers in cancer development with EV cargos, including protein and nucleic acids, having the potential to serve as biofluid-based biomarkers as discussed by the authors .